Finoriq research workspace

BIODESIX INC (BDSX) SEC Filings & Filing Highlights

Biodesix, Inc. operates as a diagnostic solutions company. Review BDSX SEC filings, filing highlights, and disclosure activity on Finoriq.

Company Snapshot

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Company

BIODESIX INC (BDSX)

Ticker

BDSX

Market Cap

$206.3M

Latest Price

$19.92

Industry

Medical Devices

Open insider transactions

BIODESIX INC (BDSX) Recent SEC Filing Highlights

Recent SEC filings, filing events, and disclosure highlights indexed for BIODESIX INC (BDSX).

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.